Eloxx Pharmaceuticals(ELOX)
$10.65+0.24 (+2.31%)
ELOX
Eloxx Pharmaceuticals financials statements
$10.65
At close:+0.24 (+2.31%)
Want to see ELOX full AI Analyst Report?
Eloxx Pharmaceuticals (ELOX) Ratios
310 Followers
Eloxx Pharmaceuticals Ratios
ELOX's free cash flow for Q3 2026 was $-4.28M. For the 2026 fiscal year, ELOX's free cash flow was increased by $0.00 and operating cash flow was $-4.28M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.31 | 0.11 | ― | 0.87 | 4.37 |
| Quick Ratio | 0.31 | 0.11 | ― | 0.87 | 4.37 |
| Cash Ratio | 0.28 | 0.00 | ― | 0.83 | 4.25 |
| Solvency Ratio | -0.35 | 0.00 | ― | -1.11 | -2.89 |
| Operating Cash Flow Ratio | -0.37 | -0.17 | ― | -1.38 | -3.52 |
| Short-Term Operating Cash Flow Coverage | -6.33 | -0.72 | ― | -8.00 | 0.00 |
| Net Current Asset Value | $ -11.91M | $ -24.34M | ― | $ -11.65M | $ 20.73M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.19 | 2.19 | ― | 0.63 | 0.30 |
| Debt-to-Equity Ratio | -0.08 | -0.27 | ― | -1.26 | 0.60 |
| Debt-to-Capital Ratio | -0.09 | -0.37 | ― | 4.91 | 0.38 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | ― | -4.07 | 0.35 |
| Financial Leverage Ratio | -0.44 | -0.12 | ― | -1.98 | 2.02 |
| Debt Service Coverage Ratio | -2.41 | 0.00 | ― | -5.35 | -51.24 |
| Interest Coverage Ratio | -6.14 | 0.00 | ― | -17.66 | -52.44 |
| Debt to Market Cap | 0.62 | 0.00 | ― | 3.18 | 0.24 |
| Interest Debt Per Share | 1.83 | 0.00 | ― | 7.08 | 8.41 |
| Net Debt to EBITDA | 0.77 | 0.00 | ― | 0.18 | 0.45 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | ― | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | ― | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | ― | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | ― | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | ― | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | ― | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | ― | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 0.00% | ― | 100.00% | 100.00% |
| EBT Per EBIT | 93.12% | 0.00% | ― | 104.78% | 101.07% |
| Return on Assets (ROA) | -113.76% | 0.00% | ― | -170.74% | -147.83% |
| Return on Equity (ROE) | 50.35% | 0.00% | ― | 338.32% | -298.10% |
| Return on Capital Employed (ROCE) | 54.07% | 0.00% | ― | 1748.93% | -187.64% |
| Return on Invested Capital (ROIC) | 59.03% | 0.00% | ― | -1263.55% | -184.20% |
| Return on Tangible Assets | -113.76% | 0.00% | ― | -170.74% | -147.83% |
| Earnings Yield | -373.48% | 0.00% | ― | -914.73% | -134.33% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | ― | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | ― | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | ― | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | ― | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | ― | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | ― | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | ― | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | ― | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | ― | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | ― | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | ― | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -5.64 | 0.00 | ― | -14.70 | -20.01 |
| Free Cash Flow Per Share | 0.00 | 0.00 | ― | -14.73 | -20.06 |
| Dividend Paid and CapEx Coverage Ratio | -1.00 | 0.00 | ― | -482.50 | -393.27 |
| Capital Expenditure Coverage Ratio | -1.00 | 0.00 | ― | -482.50 | -393.27 |
| Operating Cash Flow Coverage Ratio | -6.33 | -0.72 | ― | -2.38 | -2.60 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | ― | 0.00 | 0.00 |
| Free Cash Flow Yield | 0.00% | 0.00% | ― | -809.37% | -70.64% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.27 | 0.00 | ― | -0.11 | -0.74 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | ― | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -0.13 | 0.00 | ― | -0.37 | 2.22 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 0.00 | 0.00 | ― | -0.12 | -1.42 |
| Price-to-Operating Cash Flow Ratio | -0.25 | 0.00 | ― | -0.12 | -1.42 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | 0.00 | ― | 0.00 | -0.07 |
| Enterprise Value Multiple | 0.44 | 0.00 | ― | 0.06 | -0.32 |
| Enterprise Value | -2.19M | 6.41M | ― | -1.88M | 20.86M |
| EV to EBITDA | 0.44 | 0.00 | ― | 0.06 | -0.32 |
| EV to Sales | 0.00 | 0.00 | ― | 0.00 | 0.00 |
| EV to Free Cash Flow | 0.00 | -1.36 | ― | 0.06 | -0.59 |
| EV to Operating Cash Flow | 0.35 | -1.36 | ― | 0.06 | -0.60 |
| Tangible Book Value Per Share | -10.61 | 0.00 | ― | -4.92 | 12.80 |
| Shareholders’ Equity Per Share | -10.61 | 0.00 | ― | -4.92 | 12.80 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | ― | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | ― | 0.00 | 0.00 |
| Net Income Per Share | -5.34 | 0.00 | ― | -16.65 | -38.15 |
| Tax Burden | 1.00 | 0.00 | ― | 1.00 | 1.00 |
| Interest Burden | 1.21 | 0.00 | ― | 1.11 | 1.02 |
| Research & Development to Revenue | 0.00 | 0.00 | ― | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | ― | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | ― | 0.00 | 0.00 |
| Income Quality | 1.06 | 1.50 | ― | 0.88 | 0.52 |
Currency in USD

